Početna › Multipli mijelom
Kliničke studije za Multipli mijelom koje traže sudionike u SAD-u
239 studija za Multipli mijelom traži sudionike na lokacijama širom Sjedinjenih Američkih Država.
Gradovi s najviše studija
- New York City, NY60 studija
- Boston, MA42 studija
- Atlanta, GA41 studija
- Houston, TX38 studija
- Durham, NC37 studija
- Nashville, TN32 studija
- Denver, CO27 studija
- Rochester, MN24 studija
- St. Louis, MO24 studija
- Columbus, OH24 studija
- Baldwin Park, CA23 studija
- Chicago, IL22 studija
- Seattle, WA22 studija
- Washington, DC22 studija
- Edison, NJ22 studija
- Miami, FL21 studija
- Salt Lake City, UT21 studija
- Charlotte, NC21 studija
- Milwaukee, WI21 studija
- Queens, NY20 studija
- Detroit, MI19 studija
- Jacksonville, FL18 studija
- Birmingham, AL18 studija
- Los Angeles, CA17 studija
- Cincinnati, OH17 studija
- Dallas, TX17 studija
- Cleveland, OH16 studija
- Phoenix, AZ16 studija
- Philadelphia, PA16 studija
- Omaha, NE16 studija
- Tampa, FL15 studija
- Cedar Rapids, IA15 studija
- San Francisco, CA15 studija
- Irvine, CA14 studija
- Winston-Salem, NC14 studija
- New Rochelle, NY14 studija
- New Haven, CT14 studija
- Clifton, NJ14 studija
- Portland, OR13 studija
- Indianapolis, IN13 studija
Po državama
- Alabama22 studija
- Arizona28 studija
- Arkansas9 studija
- Colorado37 studija
- Connecticut18 studija
- Delaware4 studija
- Distrikt Columbia10 studija
- Florida55 studija
- Georgia49 studija
- Idaho3 studija
- Illinois31 studija
- Indiana19 studija
- Iowa17 studija
- Kalifornija70 studija
- Kansas12 studija
- Kentucky15 studija
- Louisiana9 studija
- Maine3 studija
- Maryland25 studija
- Massachusetts44 studija
- Michigan26 studija
- Minnesota30 studija
- Missouri27 studija
- Montana4 studija
- Nebraska18 studija
- New Hampshire4 studija
- New Jersey38 studija
- New Mexico5 studija
- New York75 studija
- North Carolina52 studija
- North Dakota5 studija
- Ohio46 studija
- Oklahoma3 studija
- Oregon20 studija
- Pennsylvania23 studija
- Rhode Island6 studija
- South Carolina9 studija
- South Dakota3 studija
- Tennessee32 studija
- Texas53 studija
- Utah21 studija
- Virginia20 studija
- Washington30 studija
- West Virginia3 studija
- Wisconsin28 studija
Nedavno ažurirane studije
Službeni tekst studije (engleski)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
U tijeku regrutacijaFaza 1
Od 18 do 120 godina · Oba spola · Ažurirano 2. lis 2026. · NCT06904066A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT07582432A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT07589634A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
U tijeku regrutacijaFaza 2
Od 60 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06679829Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06630104Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT06948084The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07285044A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT05519085SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07850284A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07409246A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07391657A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT05652335A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT04973605Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
U tijeku regrutacijaOpažajna studija
Od 18 do 120 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT02682667Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
U tijeku regrutacijaFaza 2
Od 18 do 72 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT03412877Tissue Collection for Studies of Lymph Cancer
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT01676805A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07518186A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06500884A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07073547A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06768489Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07609940A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
U tijeku regrutacijaFaza 2
Od 18 do 80 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT07149857A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07258511Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
U tijeku regrutacijaFaza 2
Od 60 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06052826A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT04634552Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.